Imunon, Inc.

Imunon, Inc. is a clinical-stage biotechnology company based in the United States, focused on developing immunotherapies and vaccines. Its primary clinical program is IMNN-001, a DNA-based immunotherapy currently in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer. IMNN-001 is also in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. The company is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. Beyond these specific programs, Imunon develops non-viral DNA technology, including TheraPlas, which is used for coding proteins and cytokines in the treatment of solid tumors, and PlaCCine, designed for coding viral antigens to elicit strong immunological responses. The company was incorporated in 1982 and changed its name from Celsion Corporation to Imunon, Inc. in September 2022. Imunon, Inc. is headquartered in Lawrenceville, New Jersey.